Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.75Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 9.17%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, financial improvements, and strategic expansions in clinical networks. While there are regulatory and market risks, the advancements and potential market opportunities appear to outweigh the challenges.Company Guidance
During the NRx Pharmaceuticals First Quarter 2025 Earnings Call, the company provided detailed guidance on several fronts, emphasizing their progress and future outlook. The company highlighted substantial advancements in their pipeline, specifically with their lead candidates, NRX-100 and NRX-101, both of which are in the regulatory process with the U.S. FDA. They reported a successful reduction in core corporate expenses and a stronger cash position compared to previous quarters. They anticipated generating revenue from their HOPE Therapeutics Clinic network and projected profitability by the end of 2025. The company is also pursuing patent protection for their preservative-free formulation of NRX-100, potentially extending market exclusivity until 2045. Financially, they reported a net loss of $5.5 million for the quarter, a decrease from the previous year's loss, with operating expenses also reduced. The company aims to achieve significant market impact with NRX-100 and NRX-101, addressing unmet medical needs for suicidal depression and akathisia, and anticipates FDA approval and revenue generation within the year.Advances in Regulatory Process
NRx has advanced its lead candidates, NRX-100 and NRX-101, in the regulatory process with the U.S. FDA, including the initiation of a new drug application for NRX-100 for the treatment of suicidal depression.
Financial Improvements
The company ended the quarter with more cash on the balance sheet than in prior quarters and reduced core corporate expenses. Net loss decreased from $6.5 million to $5.5 million year-over-year for the first quarter.
Establishment of HOPE Therapeutics
Progress in establishing the HOPE Therapeutics Clinic network across the U.S. with non-dilutive financing and acquisition of three state-of-the-art interventional psychiatry practices.
Innovative Drug Development
Filing a patent for a novel preservative-free formulation of NRX-100 potentially extending protection into 2045. Development of pH-neutral ketamine for subcutaneous administration.
Potential Market Opportunity
NRX-100 and NRX-101 represent multibillion-dollar opportunities, with expected market exclusivity and broad insurance reimbursements upon FDA approval.
NRXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $2.40 | $2.45 | +2.08% |
Mar 17, 2025 | $2.35 | $2.05 | -12.77% |
Nov 14, 2024 | $1.16 | $1.19 | +2.59% |
Aug 13, 2024 | $1.90 | $1.86 | -2.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NRX Pharmaceuticals (NRXP) report earnings?
NRX Pharmaceuticals (NRXP) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is NRX Pharmaceuticals (NRXP) earnings time?
NRX Pharmaceuticals (NRXP) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXP EPS forecast?
NRXP EPS forecast for the fiscal quarter 2025 (Q2) is -0.19.